NCT00583063View on ClinicalTrials.gov

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Solid Tumors

Interventions

DRUG

sunitinib

25 mg daily (oral dosing)

DRUG

rapamycin

4 mg daily (oral dosing)

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

University of Chicago

OTHER